Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 59 of 272 for:    Betamethasone

BETAmethasone Dose Reduction: Non-Inferiority on the Neurocognitive Outcomes of Children Born Before 32 Weeks of Gestation (BETANINO)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04021485
Recruitment Status : Not yet recruiting
First Posted : July 16, 2019
Last Update Posted : July 16, 2019
Sponsor:
Information provided by (Responsible Party):
Assistance Publique - Hôpitaux de Paris

Brief Summary:

Maternal antenatal corticosteroid therapy is the last major advance in the antenatal management of fetuses to prevent neonatal complications associated with prematurity. Long-term neurological outcomes in infants exposed to antenatal steroids have been assessed in few cohorts and suggest that this therapy is able to prevent some neurodevelopmental impairments including cerebral palsy. While >85% of neonates born very preterm in Europe have been exposed to antenatal betamethasone, Cochrane collaborative networks stated that trials of dosages comparing different regimens of commonly used corticosteroids are most urgently needed to avoid useless fetal exposure to excessive dosage of corticosteroids.

Because a half dosage was associated with maximal benefits on lung function in ewes, a randomized controlled trial (BETADOSE, NCT02897076) is currently conducted to demonstrate that a 50% reduced betamethasone dose regimen is not inferior to a full dose to prevent respiratory distress syndrome in preterm neonates. Follow-up of infants born from enrolled women is mandatory both to investigate the long-term effect of dose reduction and to confirm the non-inferiority of the dose reduction on neurocognition.

The main hypothesis of BETANINO is that half dose regimen of betamethasone is not inferior to full dose regimen of betamethasone to prevent neurodevelopmental impairments in these high-risk children born very preterm.


Condition or disease Intervention/treatment Phase
Premature Childbirth Other: neurodevelopmental assessment Not Applicable

Detailed Description:

Maternal antenatal corticosteroids (ACS) therapy is considered to be the last major advance in the antenatal management of fetuses at risk of preterm birth. It was adopted worldwide to prevent neonatal death and neonatal complications following preterm birth, including respiratory distress syndrome, necrotizing enterocolitis and severe intraventricular hemorrhage. While short-term benefits of ACS were extensively investigated, long-term neurological outcomes in infants exposed antenatally to betamethasone have been assessed in few cohorts only. A recent report from the Cochrane collaborative network suggest that ACS is able to prevent some neurodevelopmental impairments associated with preterm delivery and related to postnatal adverse events .

As of today, in Europe and France, more than 85% of neonates born very preterm have been exposed to antenatal corticosteroids, mostly betamethasone for a total dose of 24 mg. Cochrane collaborative networks stated that trials of dosages comparing different regimens of commonly used corticosteroids are most urgently needed. Because a half dosage was associated with maximal benefits on lung function in ewes, a randomized controlled trial (BETADOSE, NCT02897076) is currently conducted to demonstrate that a 50% reduced betamethasone dose regimen is not inferior to a full dose regimen to prevent respiratory distress syndrome in neonates. Whatever the results of this ongoing clinical trial, follow-up of infants born from enrolled women is mandatory both to confirm the non-inferiority of the dose reduction on neurocognition and to assess the long-term effect of dose reduction on survival, on complex aspects of cognition, on behavioral aspects and on others neurodevelopmental impairments. Indeed, changes in clinical practices following BETADOSE trials will be depending on both short- and long-term outcomes. If non inferiority is demonstrated, dramatic changes will occur in the clinical use of antenatal betamethasone in women at risk of preterm birth in France and worldwide. If non inferiority is rejected, the neurocognitive follow-up of enrolled patients will be also of interest to (i) assess the long-term impact of the early consequences associated with betamethasone dose reduction and (ii) to find out domains of neurocognitive development sensitive to ACS exposure.

BETANINO study aims at assessing the impact of a 50% dose reduction on neurocognition at 3 years of age in infants born from mothers enrolled in the BETADOSE trial before 32 weeks of gestation, children that are at highest risk of neurocognitive impairments during childhood.

The main hypothesis of this cohort study following a randomized clinical trial is that half dose betamethasone (12 mg) is not inferior to full dose betamethasone (24 mg) to prevent neurodevelopmental impairment in children born very preterm.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 786 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: 3-year Follow-up of the BETADOSE Trial: Non-inferiority of a 50% Dose Reduction of Antenatal Betamethasone Therapy on the Neurodevelopment of Children Born Before 32 Weeks of Gestation.
Estimated Study Start Date : December 1, 2019
Estimated Primary Completion Date : January 1, 2020
Estimated Study Completion Date : January 1, 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Health Checkup

Arm Intervention/treatment
neurodevelopmental assessment

As part of the usual follow-up of premature children, a follow-up consultation is planned around the age of 3 years. During this visit, a neurodevelopmental assessment will be carried out for the Betanino study. The duration of this evaluation is evaluated around 3h in total.

Interventions will include:

  • Standardized neurological exam
  • Morphometric measurements including height, weight, head circumference
  • Blood pressure measurement
  • Multiple aspects of cognition using ancillary indexes of WPPSI-IV subtests, NEPSY subtests and KABC-II (Kaufman Assessment Battery for Children II) subtests,
  • Autism spectrum disorders assessed using M-CHAT (Modified Checklist for Autism in Toddlers) questionnaire,
  • Social Relativeness, using Social Relativeness Scale parental questionnaire,
  • Parental stress using PSI questionnaire
Other: neurodevelopmental assessment

As part of the usual follow-up of premature children, a follow-up consultation is planned around the age of 3 years. During this visit, a neurodevelopmental assessment will be carried out for the Betanino study. The duration of this evaluation is evaluated around 3h in total.

Interventions will include:

  • Standardized neurological exam
  • Morphometric measurements including height, weight, head circumference
  • Blood pressure measurement
  • Multiple aspects of cognition using ancillary indexes of WPPSI-IV subtests, NEPSY subtests and KABC-II (Kaufman Assessment Battery for Children II) subtests,
  • Autism spectrum disorders assessed using M-CHAT (Modified Checklist for Autism in Toddlers) questionnaire,
  • Social Relativeness, using Social Relativeness Scale parental questionnaire,
  • Parental stress using PSI questionnaire




Primary Outcome Measures :
  1. neurocognitive development [ Time Frame: 3 years ]
    Cognition will be assessed by certified neuropsychologists at 3 years of age using full scale IQ generated by Wechsler Preschool and Primary Scale of Intelligence (WPPSI-IV) test.


Secondary Outcome Measures :
  1. 3-year survival without moderate-to-severe impairment [ Time Frame: 3 years ]
  2. neurocognitive development [ Time Frame: 3 years ]
    Measured by WPPSI-IV subtests

  3. Autism spectrum [ Time Frame: 3 years ]
    Autism spectrum disorders assessed using M-CHAT (Modified Checklist for Autism in Toddlers) questionnaire All assessments will be based on internationally recognized tests that have been validated for infants at 3 years of age and conducted by certified neuropsychologists.

  4. Parental stress [ Time Frame: 3 years ]
    Parental stress using PSI questionnaire All assessments will be based on internationally recognized tests that have been validated for infants at 3 years of age and conducted by certified neuropsychologists.

  5. cerebral palsy [ Time Frame: 3 years ]
    cerebral palsy using the GMFCS notation system,

  6. neurocognitive development [ Time Frame: 3 years ]
    Measured by NEPSY subtests

  7. neurocognitive development [ Time Frame: 3 years ]
    Measurd by KABC-II subtests (Kaufman Assessment Battery for Children II)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   34 Months to 42 Months   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Singleton child born from mother enrolled in the BETADOSE trial,
  • Gestational age at birth less than 32 weeks of gestation,
  • Age between 34 months and 42 months, alive and not lost of follow up
  • Informed consent of the holder (s) of the exercise of parental authority
  • Affiliation to a social security scheme.

Exclusion Criteria:

  • Major malformations and chromosomal aberrations evidenced after birth,
  • Parents' refuse to participate.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04021485


Contacts
Layout table for location contacts
Contact: Biran Valérie, PHD 01 40 03 41 91 valerie.biran@aphp.fr

Locations
Layout table for location information
France
Hôpital Robert Debré Not yet recruiting
Paris, Pa, France, 75019
Contact: Biran Valérie, PHD    01 40 03 41 91    valerie.biran@aphp.fr   
Sponsors and Collaborators
Assistance Publique - Hôpitaux de Paris

Layout table for additonal information
Responsible Party: Assistance Publique - Hôpitaux de Paris
ClinicalTrials.gov Identifier: NCT04021485     History of Changes
Other Study ID Numbers: K170920J
First Posted: July 16, 2019    Key Record Dates
Last Update Posted: July 16, 2019
Last Verified: July 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Betamethasone
Betamethasone Valerate
Betamethasone-17,21-dipropionate
Betamethasone benzoate
Betamethasone sodium phosphate
Premature Birth
Obstetric Labor, Premature
Obstetric Labor Complications
Pregnancy Complications
Anti-Inflammatory Agents
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Anti-Asthmatic Agents
Respiratory System Agents